Pendopharm-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Pendopharm - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014185
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PendoPharm is a healthcare company that offers production and commercialization of a wide range of drugs. The company’s products comprise spans prescription drugs, over-the-counter and behind-the-counter products. Its prescription products offers drugs for therapeutic areas of gastroenterology, orthopedics and urology. Its OTC and BTC products provide allergy, analgesics, cough, cold and sinus, gastroenterology, nasal care and pediatric drugs. The company also offers licensing, development and marketing late-stage specialty prescription medicines and consumer brands. It markets its products across Canada. Pendopharm is headquartered in Montreal, Quebec, Canada.

Pendopharm – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pendopharm, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Pendopharm, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Pendopharm, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Pendopharm, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Pendopharm, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Pendopharm, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
PendoPharm Enters into Distribution Agreement with Tillotts Pharma 10
Anika Therapeutics Enters into Agreement with PendoPharm 11
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 12
Licensing Agreements 13
Pendopharm Enters into Licensing Agreement with Edesa Biotech 13
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 14
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 15
Equity Offering 16
Sigmoid Pharma Raises USD6.3 Million in Private Placement 16
Pendopharm – Key Competitors 17
Pendopharm – Key Employees 18
Pendopharm – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Product News 20
Aug 17, 2017: Introducing the new Lax-A product line for relief of occasional constipation 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Pendopharm, Pharmaceuticals & Healthcare, Key Facts 2
Pendopharm, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Pendopharm, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Pendopharm, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Pendopharm, Deals By Therapy Area, 2011 to YTD 2017 8
Pendopharm, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PendoPharm Enters into Distribution Agreement with Tillotts Pharma 10
Anika Therapeutics Enters into Agreement with PendoPharm 11
Pendopharm Enters into Distribution Agreement with Sanofi-aventis Canada 12
Pendopharm Enters into Licensing Agreement with Edesa Biotech 13
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 14
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 15
Sigmoid Pharma Raises USD6.3 Million in Private Placement 16
Pendopharm, Key Competitors 17
Pendopharm, Key Employees 18

★海外企業調査レポート[Pendopharm-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SEGRO Plc:企業のM&A・事業提携・投資動向
    SEGRO Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SEGRO Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Wood Group Mustang Inc:企業の戦略的SWOT分析
    Wood Group Mustang Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Romelectro S.A.:企業の戦略的SWOT分析
    Romelectro S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Xbrane Biopharma AB (XBRANE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xbrane Biopharma AB (Xbrane), formerly Xbrane Bioscience AB is a biopharmaceutical company that develops and manufactures complex generic products. The company's product portfolio includes biosimilars and long acting injectables developed for people suffering from critical diseases. It combi …
  • Cantex Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cantex Pharmaceuticals Inc (Cantex Pharmaceuticals), formerly ParinGenix Inc is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combi …
  • Par Pacific Holdings, Inc. (PARR)-石油・ガス分野:企業M&A・提携分析
    Summary Par Pacific Holdings, Inc. (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company c …
  • Chemical Company of Malaysia Berhad (CCM)-製薬・医療分野:企業M&A・提携分析
    Summary Chemical Company of Malaysia Berhad (CCM) is an industrial and specialty chemicals company. Its core business activities include provision of pharmaceuticals and healthcare products; chemical products and applications; and polymer coatings and applications. The company’s product range find a …
  • NeuroMetrix Inc (NURO):医療機器:M&Aディール及び事業提携情報
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …
  • JD.com Inc:企業の戦略・SWOT・財務情報
    JD.com Inc - Strategy, SWOT and Corporate Finance Report Summary JD.com Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sarah Cannon Research Institute LLC-製薬・医療分野:企業M&A・提携分析
    Summary Sarah Cannon Research Institute LLC (SCRI) is a research institute that offers integrated cancer services. The institute conducts clinical research programs for advancing cancer therapies. Its services include blood cancer network, cancer care overview, cardiovascular research, contract rese …
  • Katrina Group Ltd. (1A0):企業の財務・戦略的SWOT分析
    Katrina Group Ltd. (1A0) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Frontier Communications Corporation:企業の戦略・SWOT・財務情報
    Frontier Communications Corporation - Strategy, SWOT and Corporate Finance Report Summary Frontier Communications Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Umecrine Cognition AB-製薬・医療分野:企業M&A・提携分析
    Summary Umecrine Cognition AB (Umecrine), a subsidiary of Umecrine AB is a developer of treatments for neurological disorders in the central nervous system. The company develops pharmaceuticals for the treatment of acute life-threatening hepatic encephalopathy (HE) and long-term maintenance in minim …
  • Europlasma SA (ALEUP):企業の財務・戦略的SWOT分析
    Europlasma SA (ALEUP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Terex Corporation:企業の戦略・SWOT・財務情報
    Terex Corporation - Strategy, SWOT and Corporate Finance Report Summary Terex Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Otrum AS:企業の戦略的SWOT分析
    Otrum AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • New Brunswick Power Corporation:企業の戦略的SWOT分析
    New Brunswick Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Oiltanking GmbH:企業の戦略的SWOT分析
    Oiltanking GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • NantKwest Inc (NK):企業の財務・戦略的SWOT分析
    Summary NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, develops natural killer (NK) cell therapies to treat cancer, infectious and inflammatory diseases by harnessing the immune system. The company is developing drugs against Merkel cell carcinoma 2L, non-small cell lung cancer 3L, multip …
  • Sanmina Corporation (SANM):企業の財務・戦略的SWOT分析
    Sanmina Corporation (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆